Biblio

Author Title [ Type

] Year

Filters: Author is Alvarez-Larran, Alberto [Clear All Filters]

Journal Article

Alvarez-Larran A, Sant'Antonio E, Harrison C, Kiladjian J-J, Griesshammer M, Mesa R, Ianotto JChristophe, Palandri F, Hernández-Boluda JCarlos, Birgegård G, et al. Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet. Lancet Haematol. 2021;8(9):e658-e665.

Marchetti M, Ghirardi A, Masciulli A, Carobbio A, Palandri F, Vianelli N, Rossi E, Betti S, Di Veroli A, Iurlo A, et al. Second cancers in MPN: survival analysis from an international study. Am J Hematol. 2019.

Kiladjian J-J, Marin FFerrer, Al-Ali HKathrin, Alvarez-Larran A, Beggiato E, Bieniaszewska M, Breccia M, Buxhofer-Ausch V, Cerna O, Crisan A-M, et al. ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options. Ann Hematol. 2024.

Hernández-Boluda J-C, Pereira A, Alvarez-Larran A, Martín A-A, Benzaquen A, Aguirre L, Mora E, González P, Mora J, Dorado N, et al. Predicting Survival after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: Performance of the Myelofibrosis Transplant Scoring System (MTSS) and Development of a New Prognostic Model: Prognostication in myelofibrosis. Biol Blood Marrow Transplant. 2020.

Marchetti M, Vannucchi AMaria, Griesshammer M, Harrison C, Koschmieder S, Gisslinger H, Alvarez-Larran A, De Stefano V, Guglielmelli P, Palandri F, et al. Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations. Lancet Haematol. 2022;9(4):e301-e311.